Efficacy of Magnetotherapy in Hand Erosive Osteoarthritis.

Sponsor
Hospital Mutua de Terrassa (Other)
Overall Status
Completed
CT.gov ID
NCT03805113
Collaborator
(none)
19
2
37

Study Details

Study Description

Brief Summary

Erosive arthritis (EA) is an unusual pathology. There is no definitive treatment and the conventional one has little efficacy. Despite using magnetotherapy (MGT) as a treatment, there is no evidence supporting its use.

Condition or Disease Intervention/Treatment Phase
  • Device: Magnetotherapy device
  • Device: Placebo
N/A

Detailed Description

The aim of the study is to evaluate the efficacy of MGT in patients suffering from hand EA, compared to placebo, in terms of pain (assessed by Visual Analog Scale (VAS)) and functionality (assessed by The Disabilities of the Arm, Shoulder and Hand (DASH) score) during the treatment and after a 3-months period. Secondarily, rigidity (Modified Kapandji Index), grip strength (JAMAR dynamometry) and quality of life (SF-36 questionnaire) were assessed. Treatment safety will also be evaluated.

Study Design

Study Type:
Interventional
Actual Enrollment :
19 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Efficacy of Magnetotherapy in Hand Erosive Osteoarthritis. A Randomized Clinical Trial.
Actual Study Start Date :
Jan 2, 2016
Actual Primary Completion Date :
May 1, 2017
Actual Study Completion Date :
Feb 2, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.

Device: Magnetotherapy device
Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.

Placebo Comparator: Control group placebo

Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.

Device: Placebo
Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.

Outcome Measures

Primary Outcome Measures

  1. Visual Analogue Scale (VAS) [Change from baseline pain at the end of the intervention and 3 months after the end of intervention.]

    The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which measures subjective characteristics or attitudes that cannot be directly measured, like pain. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points: one meaning no pain and the opposite one meaning the worst pain.

Secondary Outcome Measures

  1. The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire [Before starting the intervention, at the end of the intervention and 3 months after the end of intervention.]

    The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a self-administered region-specific outcome instrument developed as a measure of self-rated upper-extremity disability and symptoms. The DASH consists mainly of a 30-item disability/symptom scale, scored 0 (no disability) to 100.

  2. Modified Kapandji Index [Before starting the intervention, at the end of the intervention and 3 months after the end of intervention.]

    Modified Kapandji Index is a rate of hand mobility assessment. The final result is obtained by adding the results of the 3 tests: test opposition of the thumb (It consists of touching the 4 fingers with the thumb pulp. It scores from 0 to 10); fingers flexion test (It consists of following the thumb with each of the fingers, scoring from 0 (impossible to achieve) to 20 (completely achieved)); fingers extension test (It consists of stretching the hand on a table and get the maximum contact with the surface of the table, scoring from 0 (impossible to achieve) to 20 (completely achieved)).

  3. JAMAR dynamometry [Before starting the intervention, at the end of the intervention and 3 months after the end of intervention.]

    JAMAR dynamometry is a valid and reliable instrument to measure the muscular strength of the hands. It is needed to be well performed. The patient is placed in a sitting position with the elbows flexed to 90 degrees without supporting them and the JAMAR is approached to him to be able to make 3 strength determinations with each hand. The final value is extracted from the average of the 3 values of each hand.

  4. SF-36 questionnaire [Before starting the intervention, at the end of the intervention and 3 months after the end of intervention.]

    SF-36 is a self-administered questionnaire that can be answered in approximately 10 minute. It quantifies thepatients health status using 8 scales that measure three aspects: functional status, well-being and overall health assessment. 8 numbers between 0 and 100 are obtained. The higher score, the better health status is.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients of both sexes older than 18 years with symptomatic hand erosive osteoarthritis for more than 6 months.

  • Patients receiving treatment or not for their hand pathology.

  • Patients suffering from hand chronic pain due to their pathology and scoring VAS equal or greater than 4/10.

  • Patients who voluntarily signed the informed consent and agree to participate in the study.

Exclusion Criteria:
  • Pregnancy

  • Patients with pacemaker or similar devices

  • Pacients with cognitive dysfunction.

  • Patients with psychiatric pathologies unable to comply with the treatment and follow-up

  • Patients with active oncological and / or infectious pathology

  • Patients with previous magnetotherapy or paraffin treatment in the last year

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hospital Mutua de Terrassa

Investigators

  • Principal Investigator: Anna Boada-Pladellorens, MD, Hospital Nostra Senyora de Meritxell

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Anna Boada-Pladellorens, MD, Hospital Mutua de Terrassa
ClinicalTrials.gov Identifier:
NCT03805113
Other Study ID Numbers:
  • 02/16
First Posted:
Jan 15, 2019
Last Update Posted:
Nov 21, 2019
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Anna Boada-Pladellorens, MD, Hospital Mutua de Terrassa
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2019